CLINICAL_TRIALS trial_result · 2013-10-14

Clinical Trial Update: An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer [Phase 2]

Open-label Phase II trial of BIBW 2992 (afatinib) in HER2-negative metastatic breast cancer completed; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-10-14